Researchers at the Luxembourg Institute of Health (LIH) have uncovered how glioblastoma, the most aggressive form of brain cancer, influences the body’s immune system. Using single-cell technologies, the team identified distinct immune cell signatures in patients’ blood, providing new insights into disease progression and opening opportunities for future blood-based biomarkers and targeted therapies.